Analysts Set Bausch Health Cos Inc. (NYSE:BHC) PT at $8.50

Bausch Health Cos Inc. (NYSE:BHC) has been assigned a consensus rating of “Hold” from the five ratings firms that are currently covering the company, MarketBeat reports. Five analysts have rated the stock with a hold recommendation. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $8.6667.

A number of research firms recently issued reports on BHC. Truist Financial raised their price objective on shares of Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a report on Wednesday, January 7th. Raymond James Financial reissued a “market perform” rating on shares of Bausch Health Cos in a research report on Monday, January 26th. Weiss Ratings restated a “hold (c)” rating on shares of Bausch Health Cos in a research note on Monday, December 29th. Barclays assumed coverage on Bausch Health Cos in a report on Monday, December 8th. They set an “equal weight” rating and a $8.00 price target for the company. Finally, Wall Street Zen raised Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 7th.

Bausch Health Cos Stock Down 1.3%

Bausch Health Cos stock opened at $6.08 on Thursday. Bausch Health Cos has a one year low of $4.25 and a one year high of $8.69. The stock has a fifty day moving average of $6.75 and a 200 day moving average of $6.70. The company has a debt-to-equity ratio of 57.48, a quick ratio of 0.97 and a current ratio of 1.30. The stock has a market cap of $2.25 billion, a PE ratio of 6.27 and a beta of 0.42.

Hedge Funds Weigh In On Bausch Health Cos

Hedge funds have recently modified their holdings of the company. Goldentree Asset Management LP increased its stake in shares of Bausch Health Cos by 1.7% in the third quarter. Goldentree Asset Management LP now owns 34,833,431 shares of the company’s stock worth $224,409,000 after purchasing an additional 578,542 shares in the last quarter. Paulson & CO. Inc. boosted its holdings in Bausch Health Cos by 24.0% in the 2nd quarter. Paulson & CO. Inc. now owns 32,791,702 shares of the company’s stock worth $218,393,000 after buying an additional 6,352,667 shares during the period. Vanguard Group Inc. increased its stake in Bausch Health Cos by 4.0% in the 3rd quarter. Vanguard Group Inc. now owns 12,241,072 shares of the company’s stock worth $78,808,000 after buying an additional 470,968 shares in the last quarter. Maple Rock Capital Partners Inc. raised its holdings in Bausch Health Cos by 14.9% during the second quarter. Maple Rock Capital Partners Inc. now owns 7,808,487 shares of the company’s stock valued at $52,005,000 after acquiring an additional 1,010,987 shares during the period. Finally, SG Americas Securities LLC lifted its position in shares of Bausch Health Cos by 114.4% in the second quarter. SG Americas Securities LLC now owns 6,152,986 shares of the company’s stock valued at $40,979,000 after acquiring an additional 3,282,684 shares in the last quarter. 78.65% of the stock is currently owned by institutional investors.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.